Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Background: We investigated outcomes with cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC) with or without prior nephrectomy in the phase 3 METEOR trial (NCT01865747). Methods: Patients (N = 658) with advanced clear cell RCC and prior treatment with≥1 VEGFR tyrosin...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Nizar M. Tannir, Thomas Powles, Bernard Escudier, Frede Donskov, Viktor Grünwald, Cora N. Sternberg, Manuela Schmidinger, Patrick Schöffski, Cezary Szczylik, Katriina Peltolta, Dmitry Nosov, Bohuslav Melichar, Douglas Clary, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	SAGE Publishing 2020-03-01
Rangatū:	Kidney Cancer
Urunga tuihono:	https://doi.org/10.3233/KCA-190080
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!